- Home
- PSNL vs ALVR Comparison
PSNL vs ALVR Comparison
Compare PSNL & ALVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNL
- ALVR
- Stock Information
- Founded
- PSNL 2011
- ALVR 2013
- Country
- PSNL United States
- ALVR United States
- Employees
- PSNL N/A
- ALVR N/A
- Industry
- PSNL Medical Specialities
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PSNL Health Care
- ALVR Health Care
- Exchange
- PSNL Nasdaq
- ALVR Nasdaq
- Market Cap
- PSNL 321.1M
- ALVR 87.7M
- IPO Year
- PSNL 2019
- ALVR 2020
- Fundamental
- Price
- PSNL $5.19
- ALVR $0.90
- Analyst Decision
- PSNL Strong Buy
- ALVR Sell
- Analyst Count
- PSNL 4
- ALVR 5
- Target Price
- PSNL $6.81
- ALVR $1.00
- AVG Volume (30 Days)
- PSNL 439.4K
- ALVR 155.6K
- Earning Date
- PSNL 11-06-2024
- ALVR 11-04-2024
- Dividend Yield
- PSNL N/A
- ALVR N/A
- EPS Growth
- PSNL N/A
- ALVR N/A
- EPS
- PSNL N/A
- ALVR N/A
- Revenue
- PSNL $80,027,000.00
- ALVR N/A
- Revenue This Year
- PSNL $10.85
- ALVR N/A
- Revenue Next Year
- PSNL $8.77
- ALVR N/A
- P/E Ratio
- PSNL N/A
- ALVR N/A
- Revenue Growth
- PSNL 19.20
- ALVR N/A
- 52 Week Low
- PSNL $0.89
- ALVR $0.58
- 52 Week High
- PSNL $7.20
- ALVR $2.49
- Technical
- Relative Strength Index (RSI)
- PSNL 56.29
- ALVR 69.10
- Support Level
- PSNL $4.54
- ALVR $0.74
- Resistance Level
- PSNL $5.35
- ALVR $0.91
- Average True Range (ATR)
- PSNL 0.30
- ALVR 0.06
- MACD
- PSNL 0.05
- ALVR 0.01
- Stochastic Oscillator
- PSNL 84.71
- ALVR 94.50
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.